IP Library Granted Patent US 8,709,441
Granted Patent B2
US 8,709,441 · App. 12/831,017 · Granted Apr 29, 2014

TC-83-derived alphavirus vectors, particles and methods

Inventors: Jon O. Rayner (Apex, NC); Jonathan F. Smith (Cary, NC); Bolyn Hubby (Chapel Hill, NC); Elizabeth A. Reap (Durham, NC)
Assignee: Alphavax, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,709,441
App. No.
12/831,017
Granted
Apr 29, 2014
Kind
B2
Abstract

The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.

Claims (7)

1. A method of producing an immune response to an immunogen heterologous to an alphavirus in a subject, comprising administering to the subject an effective amount of a composition comprising infectious, propagation-defective alphavirus particles and a pharmaceutically-acceptable carrier, wherein each particle comprises an alphavirus replicon RNA comprising an alphavirus packaging signal and one or more heterologous RNA sequence(s) encoding an immunogen heterologous to the alphavirus, and wherein said alphavirus replicon RNA lacks sequences encoding alphavirus structural proteins, and wherein each particle comprises structural proteins from Venezuelan equine encephalitis virus TC-83.

2. The method of claim 1 , wherein the composition is administered via intramuscular, subcutaneous or intraperitoneal injection.

3. The method of claim 1 , wherein the alphavirus replicon RNA is from Venezuelan equine encephalitis virus.

4. The method of claim 1 , wherein there is one heterologous RNA sequence or wherein there are two heterologous RNA sequences.

5. A method of producing an immune response in a subject, comprising administering to the subject an effective amount of a composition comprising infectious, propagation-defective alphavirus replicon particles and a pharmaceutically-acceptable carrier, wherein each particle comprises a Venezuelan equine encephalitis (VEE) TC-83-derived alphavirus replicon RNA, said replicon RNA comprising a 5′ sequence of VEE strain TC-83 RNA which initiates transcription of alphavirus RNA, one or more nucleotide sequences which together encode TC-83 alphavirus nonstructural proteins necessary for replication of the replicon RNA, an alphavirus packaging signal and one or more heterologous RNA sequence(s) encoding an immunogen heterologous to VEE TC-83, and a 3′ RNA polymerase recognition sequence of VEE strain TC-83 wherein said alphavirus replicon RNA lacks sequences encoding alphavirus structural proteins, and wherein each particle comprises structural proteins from Venezuelan equine encephalitis virus TC-83.

6. The method of claim 5 , wherein the composition is administered via intramuscular, subcutaneous or intraperitoneal injection.

7. The method of claim 5 , wherein there is one heterologous RNA sequence or wherein there are two heterologous RNA sequences in said replicon RNA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2010
From: RAYNER, JON O.; SMITH, JONATHAN F.; HUBBY, BOLYN; REAP, ELIZABETH A.
To: ALPHAVAX, INC.
Reel/Frame 025106/0470 →
Continuity (3)
Continuation 11132711 · May 18, 2005
Provisional Application 60572212 · May 18, 2004
Related Publication 20110027306A1 · Feb 3, 2011